Beyond Zero Duty: Can the India–UK FTA Unlock a New Era for Indian Pharma in Britain?

Why tariff-free access is only the beginning for pharmaceutical, biotech, medical device and life sciences companies.

India is often described as the “pharmacy of the world.” The United Kingdom, meanwhile, is one of the world’s most sophisticated pharmaceutical and life sciences markets, with a strong research ecosystem, globally recognised universities, major pharmaceutical companies and one of the world’s largest publicly funded healthcare systems.

The India–UK Comprehensive Economic and Trade Agreement (“CETA” or the “India–UK FTA”) therefore brings together two countries with highly complementary strengths. For Indian pharmaceutical companies, the headline opportunity is clear: improved access to the UK market through preferential tariff treatment. However, the larger commercial reality is far more nuanced.

Zero customs duty does not mean zero regulatory barriers.

A pharmaceutical product may qualify for preferential tariff treatment under the India–UK FTA and still be unable to enter the UK market unless it satisfies the UK’s stringent regulatory requirements.

For pharmaceutical and life sciences companies, the FTA should therefore be viewed not merely as a tariff agreement but as an instrument that could deepen integration between Indian manufacturing capabilities and the UK’s pharmaceutical, biotechnology, healthcare and innovation ecosystem.

The opportunities extend across:

• Generic medicines
• Biosimilars
• Active pharmaceutical ingredients (APIs)
• Contract development and manufacturing (CDMO)
• Clinical research
• Medical devices
• Biotechnology
• Digital health
• Pharmaceutical research and development
• Cross-border investments and acquisitions

The businesses that stand to benefit the most will be those that understand both dimensions of market access: trade access and regulatory access.

Why the India–UK Pharmaceutical Corridor Matters

India has developed one of the world’s largest pharmaceutical manufacturing ecosystems. Indian companies supply affordable medicines to over 200 countries and are global leaders in generic pharmaceuticals, vaccines and APIs. India also possesses considerable manufacturing scale, competitive production costs and an increasingly sophisticated regulatory compliance framework.

The United Kingdom offers a complementary ecosystem. It is home to internationally recognised pharmaceutical innovators, biotechnology companies, leading academic institutions, advanced clinical research infrastructure and one of the world’s most significant healthcare purchasers through the National Health Service (NHS).

The India–UK FTA creates an opportunity to connect these complementary strengths. Lower tariffs can improve price competitiveness, but sustainable growth will depend upon regulatory compliance, commercial partnerships, investment and innovation.

Zero Duty Does Not Mean Automatic Market Access

This is perhaps the most important message for pharmaceutical businesses. Trade law and pharmaceutical regulation perform entirely different functions.

The FTA determines whether a qualifying pharmaceutical product may receive preferential customs treatment. It does not determine whether that medicine can legally be manufactured, imported, marketed or supplied in the United Kingdom.

Indian pharmaceutical companies must continue to comply with all applicable UK regulatory requirements before commercialisation. Depending upon the product category, these requirements may include:

• Marketing authorisations
• Good Manufacturing Practice (GMP) compliance
• Good Distribution Practice (GDP)
• Quality assurance systems
• Pharmacovigilance obligations
• Product labelling
• Packaging standards
• Stability and safety requirements
• Clinical evidence where applicable
• Post-market surveillance obligations

Consequently, a company may possess a commercially attractive product that qualifies for preferential tariff treatment but still require extensive regulatory approvals before it can enter the UK market.

The MHRA Remains the Gatekeeper

For medicines and medical products entering the UK, regulatory approval remains central. The Medicines and Healthcare products Regulatory Agency (MHRA) continues to regulate medicines, biological products and medical devices placed on the UK market.

Indian companies seeking expansion into Britain should evaluate regulatory readiness at an early stage rather than treating regulatory approvals as a post-contract exercise. Among other issues, businesses should assess:

• The appropriate regulatory pathway for the product
• Dossier preparation requirements
• Product classification
• GMP inspections and manufacturing compliance
• Import and distribution licensing
• Pharmacovigilance infrastructure
• Post-market reporting obligations
• Ongoing regulatory compliance

For companies unfamiliar with UK regulatory requirements, early engagement with local regulatory advisors can substantially reduce delays and minimise commercial risk.

Rules of Origin Continue to Matter

Even though pharmaceutical tariffs are expected to reduce significantly under the FTA, preferential treatment is not automatic. Companies must satisfy the applicable Rules of Origin (RoO) to claim preferential tariff benefits.

For pharmaceutical manufacturers operating complex international supply chains, origin determination may require careful analysis of:

• Sourcing of APIs
• Imported intermediates
• Manufacturing operations undertaken in India
• Substantial transformation requirements
• Regional value content where applicable
• Documentary compliance

Manufacturers relying heavily on imported ingredients should review whether their production processes satisfy the origin requirements before assuming that preferential tariffs will be available.

Robust origin documentation, supplier declarations and record-keeping will become increasingly important for customs compliance.

Intellectual Property Remains a Strategic Consideration

The pharmaceutical industry operates within one of the world’s most sophisticated intellectual property environments. Although the India–UK FTA seeks to facilitate trade, businesses must continue to navigate:

• Patent protection
• Trademark registration
• Copyright
• Confidential information
• Trade secrets
• Technology licensing
• Regulatory exclusivity regimes where applicable

Generic manufacturers, biosimilar developers and innovative pharmaceutical companies should carefully evaluate freedom-to-operate analyses before entering the UK market.

Similarly, UK companies collaborating with Indian manufacturers should ensure that licensing agreements, manufacturing contracts and technology transfer arrangements clearly allocate ownership of intellectual property, improvements, confidential information and regulatory responsibilities.

Opportunities Beyond Finished Medicines

The commercial opportunities created by the FTA extend well beyond exports of finished pharmaceutical formulations.

Active Pharmaceutical Ingredients

India is a leading producer of APIs. Reduced trade barriers may encourage greater API exports to UK manufacturers seeking diversified and resilient supply chains.

Contract Development and Manufacturing

The UK’s pharmaceutical innovators increasingly utilise specialised manufacturing partners. Indian CDMOs with internationally recognised quality systems may find expanded opportunities for manufacturing and development services.

Biosimilars

India has emerged as a significant biosimilar manufacturer. As demand for affordable biological medicines continues to increase globally, Indian manufacturers with robust regulatory capabilities may be well positioned to serve the UK market.

Medical Devices

Medical device manufacturers may also benefit from improved commercial access under the FTA. Nevertheless, compliance with UK product standards, conformity assessment requirements and applicable regulatory approvals will remain essential before market entry.

Clinical Research and Innovation

The agreement also has the potential to encourage greater collaboration in research and innovation.

What India Offers

• A large patient population
• Skilled scientific professionals
• Experienced clinical research organisations
• Expanding biotechnology capabilities
• Increasingly sophisticated research infrastructure

What the UK Contributes

• Globally recognised universities
• Advanced biomedical research
• Significant venture capital investment
• Innovative pharmaceutical companies
• World-leading clinical research expertise

Potential Areas of Collaboration

These complementary strengths may facilitate:

• Joint clinical trials
• Collaborative R&D programmes
• Technology transfer
• Biotechnology partnerships
• Digital health innovation
• Academic-industry collaborations

Such arrangements, however, require carefully drafted agreements governing intellectual property ownership, data rights, confidentiality, publication rights, regulatory responsibilities and dispute resolution.

Cross-Border Investment and M&A

The FTA is also expected to encourage greater investment activity within the life sciences sector. Potential transactions may include:

• Acquisitions of pharmaceutical businesses
• Manufacturing joint ventures
• Research collaborations
• Strategic alliances
• Licensing arrangements
• Distribution partnerships
• Investments in biotechnology and medical device companies

Cross-border healthcare transactions invariably require detailed legal due diligence covering regulatory licences, manufacturing compliance, product portfolios, intellectual property, employment matters, litigation exposure, competition law considerations and tax implications.

Early legal review often identifies regulatory risks that may materially affect transaction value.

Compliance Will Become a Competitive Advantage

As trade volumes increase, regulatory scrutiny is also likely to intensify. Businesses should therefore strengthen internal compliance frameworks covering:

• Quality management systems
• Supply chain traceability
• Anti-counterfeiting measures
• Customs documentation
• Sanctions screening
• Anti-bribery compliance
• ESG obligations
• Data protection
• Product recall procedures

For pharmaceutical companies operating across multiple jurisdictions, compliance is increasingly becoming a competitive differentiator rather than merely a legal obligation.

Practical Steps for Businesses

Companies intending to leverage the India–UK FTA should consider undertaking a structured legal and commercial review covering:

• Eligibility for preferential tariff treatment under the Rules of Origin
• UK regulatory approvals and licensing requirements
• Manufacturing and GMP readiness
• Intellectual property strategy
• Distribution and commercial agreements
• Customs and trade compliance procedures
• Product liability risk allocation
• Supply chain resilience
• Dispute resolution mechanisms in cross-border contracts

Businesses that integrate trade strategy with regulatory planning are likely to realise the greatest long-term benefits from the agreement.

Conclusion

The India–UK FTA has the potential to strengthen one of the world’s most important pharmaceutical trade corridors. For Indian pharmaceutical companies, preferential tariff treatment may improve competitiveness in the UK market. However, tariff liberalisation represents only one component of successful market entry.

Regulatory compliance, intellectual property management, contractual structuring, customs compliance and strategic partnerships will continue to determine whether businesses can convert preferential market access into sustainable commercial success.

The pharmaceutical companies that benefit most from the India–UK FTA will not simply be those that manufacture competitively. They will be those that combine manufacturing excellence with robust legal compliance, regulatory preparedness and well-structured cross-border commercial strategies.

As the agreement is implemented, businesses should view the FTA not merely as a customs concession, but as a catalyst for deeper collaboration between two globally significant life sciences ecosystems. Those that prepare early—by aligning trade, regulatory and commercial strategies—will be best placed to capitalise on the next phase of India–UK pharmaceutical cooperation.

Last Updated on 28 July, 2026